Agency Forms Undergoing Paperwork Reduction Act Review, 68887 [E7-23633]
Download as PDF
<![CDATA[
68887
Federal Register / Vol. 72, No. 234 / Thursday, December 6, 2007 / Notices
mail to omb@cdc.gov. Send written
comments to CDC Desk Officer, Office of
Management and Budget, Washington,
DC or by fax to (202) 395–6974. Written
comments should be received within 30
days of this notice.
Comments submitted in response to
this notice will be summarized and
included in the Agency’s subsequent
request for OMB approval of the
proposed information collection. All
comments will become a matter of
public record.
Proposed Project
Dated: November 29, 2007.
Carolyn M. Clancy,
Director.
[FR Doc. 07–5950 Filed 12–05–07; 8:45 am]
Gonococcal Isolate Surveillance
Project (GISP)—Revision—National
Center for HIV/AIDS, Viral Hepatitis,
STD, and TB Prevention (NCHHSTP),
Centers for Disease Control and
Prevention (CDC).
BILLING CODE 4160–90–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Background and Brief Description
CDC is requesting a 3-year revision
with change for this project. The
objectives of GISP are to monitor trends
in antimicrobial susceptibility of strains
of Neisseria gonorrhoeae in the U.S. and
characterize resistant isolates. GISP
provides critical surveillance for
antimicrobial resistance, allowing for
informed treatment recommendations.
This project began in 1986 as a
voluntary surveillance project and has
involved 5 regional laboratories and 30
publicly-funded, sexually transmitted
disease (STD) clinics around the
country. The STD clinics submit up to
25 gonococcal isolates per month to the
regional laboratories, which measure
Centers for Disease Control and
Prevention
[30Day–08–0307]
Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) publishes a list of
information collection requests under
review by the Office of Management and
Budget (OMB) in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
requests, call the CDC Reports Clearance
Officer at (404) 639–5960 or send an e-
susceptibility to a panel of antibiotics.
Limited demographic and clinical
information corresponding to the
isolates are submitted directly by the
STD clinics to CDC.
During 1986–2006, GISP has
demonstrated the ability to effectively
achieve its objectives. The emergence of
resistance in the United States to
penicillin, tetracyclines, and now
fluoroquinolones was identified through
GISP and makes ongoing surveillance
critical. Increased prevalence of
fluoroquinolone-resistant N.
gonorrhoeae (QRNG) as seen in GISP
data has prompted the CDC to update
the treatment recommendations for
gonorrhea in the CDC’s Sexually
Transmitted Diseases Treatment
Guidelines, 2006 and to release an
MMWR article stating the CDC no
longer recommends fluoroquinolones
for treatment of gonococcal infections
(CDC, MMWR, Vol.56, No.14, 332–336).
Respondents are paid by Federal funds
through the CDC Comprehensive STD
Prevention Systems, Prevention of STDRelated Infertility, and Syphilis
Elimination Grant (CSPS), for their
participation in GISP network. The
estimated annualized burden for this
data collection is 8,628 hours.
ESTIMATED ANNUALIZED BURDEN HOURS
No. of
respondents
No. of responses per respondent
Avg. burden
per response
(in hours)
Type of respondent
Form name
Clinic ....................................................................
Laboratory ............................................................
Form 1 .................................................
Form 2 .................................................
Form 3 .................................................
30
5
5
240
1,452
48
11/60
1
12/60
Total ..............................................................
..............................................................
40
..........................
..........................
Dated: November 28, 2007.
Maryam I. Daneshvar,
Acting Reports Clearance Officer.
[FR Doc. E7–23633 Filed 12–5–07; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
mstockstill on PROD1PC66 with NOTICES
[60Day–08–0263]
Proposed Data Collections Submitted
for Public Comment and
Recommendations
In compliance with the requirement
of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for
opportunity for public comment on
proposed data collection projects, the
VerDate Aug<31>2005
18:57 Dec 05, 2007
Jkt 214001
Centers for Disease Control and
Prevention (CDC) will publish periodic
summaries of proposed projects. To
request more information on the
proposed projects or to obtain a copy of
the data collection plans and
instruments, call 404–639–5960 and
send comments to Maryam I. Daneshvar,
CDC Acting Reports Clearance Officer,
1600 Clifton Road, MS–D74, Atlanta,
GA 30333 or send an e-mail to
omb@cdc.gov.
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Written comments should
be received within 60 days of this
notice.
Proposed Project
Requirements for a Special Permit to
Import Cynomolgus, African Green, or
Rhesus Monkeys into the United
States—Extension—National Center for
Preparedness, Detection, and Control of
Infectious Diseases (NCPDCID), Centers
for Disease Control and Prevention
(CDC).
Background and Brief Description
CDC is requesting OMB approval to
continue its data collection,
‘‘Requirements for a Special Permit to
E:\FR\FM\06DEN1.SGM
06DEN1
]]>Agencies
[Federal Register Volume 72, Number 234 (Thursday, December 6, 2007)]
[Notices]
[Page 68887]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-23633]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-08-0307]
Agency Forms Undergoing Paperwork Reduction Act Review
The Centers for Disease Control and Prevention (CDC) publishes a
list of information collection requests under review by the Office of
Management and Budget (OMB) in compliance with the Paperwork Reduction
Act (44 U.S.C. Chapter 35). To request a copy of these requests, call
the CDC Reports Clearance Officer at (404) 639-5960 or send an e-mail
to omb@cdc.gov. Send written comments to CDC Desk Officer, Office of
Management and Budget, Washington, DC or by fax to (202) 395-6974.
Written comments should be received within 30 days of this notice.
Proposed Project
Gonococcal Isolate Surveillance Project (GISP)--Revision--National
Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP),
Centers for Disease Control and Prevention (CDC).
Background and Brief Description
CDC is requesting a 3-year revision with change for this project.
The objectives of GISP are to monitor trends in antimicrobial
susceptibility of strains of Neisseria gonorrhoeae in the U.S. and
characterize resistant isolates. GISP provides critical surveillance
for antimicrobial resistance, allowing for informed treatment
recommendations.
This project began in 1986 as a voluntary surveillance project and
has involved 5 regional laboratories and 30 publicly-funded, sexually
transmitted disease (STD) clinics around the country. The STD clinics
submit up to 25 gonococcal isolates per month to the regional
laboratories, which measure susceptibility to a panel of antibiotics.
Limited demographic and clinical information corresponding to the
isolates are submitted directly by the STD clinics to CDC.
During 1986-2006, GISP has demonstrated the ability to effectively
achieve its objectives. The emergence of resistance in the United
States to penicillin, tetracyclines, and now fluoroquinolones was
identified through GISP and makes ongoing surveillance critical.
Increased prevalence of fluoroquinolone-resistant N. gonorrhoeae (QRNG)
as seen in GISP data has prompted the CDC to update the treatment
recommendations for gonorrhea in the CDC's Sexually Transmitted
Diseases Treatment Guidelines, 2006 and to release an MMWR article
stating the CDC no longer recommends fluoroquinolones for treatment of
gonococcal infections (CDC, MMWR, Vol.56, No.14, 332-336). Respondents
are paid by Federal funds through the CDC Comprehensive STD Prevention
Systems, Prevention of STD-Related Infertility, and Syphilis
Elimination Grant (CSPS), for their participation in GISP network. The
estimated annualized burden for this data collection is 8,628 hours.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
No. of Avg. burden
Type of respondent Form name No. of responses per per response
respondents respondent (in hours)
----------------------------------------------------------------------------------------------------------------
Clinic.............................. Form 1................. 30 240 11/60
Laboratory.......................... Form 2................. 5 1,452 1
Form 3................. 5 48 12/60
---------------------------------------------------------------------------
Total........................... ....................... 40 ............... ...............
----------------------------------------------------------------------------------------------------------------
Dated: November 28, 2007.
Maryam I. Daneshvar,
Acting Reports Clearance Officer.
[FR Doc. E7-23633 Filed 12-5-07; 8:45 am]
BILLING CODE 4163-18-P
